Company intelligence / Profile preview
Suzhong Pharmaceutical Group
Taizhou, Jiangsu, Chinasuzhongyy.com ↗
- Ownership
- Private
- Employees
- ~3000
- Development stage
- Other
01
Overview
Suzhong’s Sutetinib Maleate capsule for NSCLC with rare EGFR mutations achieved an objective response rate of approximately 92.9% in a Phase 2a clinical trial. The company also holds patents on novel mineralocorticoid receptor antagonists for various metabolic and cardiovascular diseases.
- Therapeutic areas
- GastroenterologyEndocrinologyOncologyNephrologyCardiovascular
- Modalities
- Small moleculeBiologicNatural medicine
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
Collaborations with Chinese Academy of SciencesZhejiang UniversityChina Pharmaceutical UniversityNanjing University of Chinese Medicine and Paris Public Hospitals Group
Beyond the preview
Go deeper on Suzhong Pharmaceutical Group.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Suzhong Pharmaceutical Group.